NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

Clinical trial NCT06405490 · RECRUITING

Trial details

NCT number: NCT06405490
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Nanoliposomal Irinotecan Cadonilimab Oxaliplatin Capecitabine First-Line Advanced Cancer Pancreatic Adenocarcinoma Drug Use

Start date: 2024-04-17
Primary completion: 2026-08-30
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.